Literature DB >> 16483847

Pathogenic role of anti-neutrophil cytoplasmic antibodies in vasculitis.

Tanya Pankhurst1, Caroline O S Savage.   

Abstract

The pathogenicity of anti-neutrophil cytoplasmic antibodies (ANCAs) in ANCA-associated vasculitis has been debated for some time. Animal models have recently demonstrated that ANCAs are a transferable cause of disease and this is supported by studies of the effects of ANCAs on neutrophil-endothelial cell interactions under flow. ANCAs activate neutrophils by cross-linking target antigens on the neutrophil surface with Fc receptors, thereby recruiting signal transduction pathways that promote neutrophil adhesion, degranulation and respiratory burst. Activated neutrophils in proximity with endothelial cells are believed to initiate injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16483847     DOI: 10.1016/j.coph.2005.10.009

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  4 in total

1.  A dual role for diacylglycerol kinase generated phosphatidic acid in autoantibody-induced neutrophil exocytosis.

Authors:  Neil J Holden; Caroline O S Savage; Stephen P Young; Michael J Wakelam; Lorraine Harper; Julie M Williams
Journal:  Mol Med       Date:  2011-08-08       Impact factor: 6.354

Review 2.  Leukocytes in glomerular injury.

Authors:  Stephen R Holdsworth; Peter G Tipping
Journal:  Semin Immunopathol       Date:  2007-10-16       Impact factor: 9.623

3.  Peripheral neuropathy in Wegener's granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis.

Authors:  Luigi Cattaneo; Elisabetta Chierici; Laura Pavone; Chiara Grasselli; Paolo Manganelli; Carlo Buzio; Giovanni Pavesi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02-13       Impact factor: 10.154

4.  Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis.

Authors:  V C Primo; S Marusic; C C Franklin; W H Goldmann; C G Achaval; R N Smith; M A Arnaout; B Nikolic
Journal:  Clin Exp Immunol       Date:  2009-12-14       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.